16,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Currently corticosteroid is the mainstay in treatment of chronic inflammatory diseases, but many chronic inflammatory diseases are resistant to corticosteroid like COPD (chronic obstructive pulmonary disease), atherosclerosis derived diseases, etc., and therefore there is an urgent need to develop new anti-inflammatory drugs. A lot of efforts have been made to develop new anti-inflammatory drugs by researchers in the last six decades, but so far there has been no break-through. Corticosteroid resistant chronic inflammation still remains a big issue in clinical practicing. It is very difficult…mehr

Produktbeschreibung
Currently corticosteroid is the mainstay in treatment of chronic inflammatory diseases, but many chronic inflammatory diseases are resistant to corticosteroid like COPD (chronic obstructive pulmonary disease), atherosclerosis derived diseases, etc., and therefore there is an urgent need to develop new anti-inflammatory drugs. A lot of efforts have been made to develop new anti-inflammatory drugs by researchers in the last six decades, but so far there has been no break-through. Corticosteroid resistant chronic inflammation still remains a big issue in clinical practicing. It is very difficult to find a new way of developing new anti-inflammatory drugs. Moxa (Artemisia Argyi) is a plant. Moxa tar is the burning product of its leaves, it has potent and unique anti-inflammatory property. Not only it can effectively treat corticosteroid resistant chronic inflammation, but also can terminate chronic self-perpetuating inflammation. It is a promising source for developing new anti-inflammation drugs. In this book, the author will give an introduction to its anti-inflammatory effect.
Autorenporträt
Doctor Qian Zeng graduated from the Second Beijing Medical College in China 1983. He migrated to Australia from China in 1985 and worked as a resident doctor in a hospital from 1997 to 2000.He did self-research on anti-inflammatory therapy for chronic inflammatory diseases from 2001 to 2011 and worked as a general practitioner from 2012 to 2016.